Cargando…
Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations
BACKGROUND: Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. OBJECTIVE: To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. METHODS: Pat...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Dermatological Association; The Korean Society for Investigative Dermatology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082003/ https://www.ncbi.nlm.nih.gov/pubmed/33935454 http://dx.doi.org/10.5021/ad.2021.33.2.131 |
_version_ | 1783685758343708672 |
---|---|
author | Yang, Seungkeol Kim, Bo Ri Kim, Minsu Youn, Sang Woong |
author_facet | Yang, Seungkeol Kim, Bo Ri Kim, Minsu Youn, Sang Woong |
author_sort | Yang, Seungkeol |
collection | PubMed |
description | BACKGROUND: Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. OBJECTIVE: To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. METHODS: Patients were evaluated using the Nail Psoriasis Severity Index (NAPSI) at every injection visit. NAPSI score changes throughout the treatment were analyzed. The treatment response in each toenail and each NAPSI characteristic was also analyzed. RESULTS: A total of 22 patients with chronic plaque psoriasis with concomitant toenail psoriasis were examined. Several characteristics such as ridging or onychomycosis that mimic psoriasis or hinder the evaluation were identified. NAPSI significantly improved during the treatment (p<0.05). The big and second toes were significantly improved after 52 weeks of ustekinumab treatment (p<0.05). Pitting and oil-drop discoloration were the only two characteristics that showed significant changes post-treatment (p<0.05). CONCLUSION: Ustekinumab proved to be efficacious in treating toenail psoriasis. Because of the factors that hinder the NAPSI scoring, only NAPSI scores of the first and second toes can be used. |
format | Online Article Text |
id | pubmed-8082003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Korean Dermatological Association; The Korean Society for Investigative Dermatology |
record_format | MEDLINE/PubMed |
spelling | pubmed-80820032021-04-30 Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations Yang, Seungkeol Kim, Bo Ri Kim, Minsu Youn, Sang Woong Ann Dermatol Original Article BACKGROUND: Nail psoriasis is a common clinically significant symptom of psoriasis. However, few studies have focused on the characteristics and course of toenail psoriasis. OBJECTIVE: To investigate the treatment response of toenail psoriasis during a 52-week period of ustekinumab use. METHODS: Patients were evaluated using the Nail Psoriasis Severity Index (NAPSI) at every injection visit. NAPSI score changes throughout the treatment were analyzed. The treatment response in each toenail and each NAPSI characteristic was also analyzed. RESULTS: A total of 22 patients with chronic plaque psoriasis with concomitant toenail psoriasis were examined. Several characteristics such as ridging or onychomycosis that mimic psoriasis or hinder the evaluation were identified. NAPSI significantly improved during the treatment (p<0.05). The big and second toes were significantly improved after 52 weeks of ustekinumab treatment (p<0.05). Pitting and oil-drop discoloration were the only two characteristics that showed significant changes post-treatment (p<0.05). CONCLUSION: Ustekinumab proved to be efficacious in treating toenail psoriasis. Because of the factors that hinder the NAPSI scoring, only NAPSI scores of the first and second toes can be used. The Korean Dermatological Association; The Korean Society for Investigative Dermatology 2021-04 2021-03-08 /pmc/articles/PMC8082003/ /pubmed/33935454 http://dx.doi.org/10.5021/ad.2021.33.2.131 Text en Copyright © 2021 The Korean Dermatological Association and The Korean Society for Investigative Dermatology https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Yang, Seungkeol Kim, Bo Ri Kim, Minsu Youn, Sang Woong Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations |
title | Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations |
title_full | Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations |
title_fullStr | Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations |
title_full_unstemmed | Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations |
title_short | Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations |
title_sort | toenail psoriasis during ustekinumab therapy: results and limitations |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082003/ https://www.ncbi.nlm.nih.gov/pubmed/33935454 http://dx.doi.org/10.5021/ad.2021.33.2.131 |
work_keys_str_mv | AT yangseungkeol toenailpsoriasisduringustekinumabtherapyresultsandlimitations AT kimbori toenailpsoriasisduringustekinumabtherapyresultsandlimitations AT kimminsu toenailpsoriasisduringustekinumabtherapyresultsandlimitations AT younsangwoong toenailpsoriasisduringustekinumabtherapyresultsandlimitations |